Company Legal Name
Latest Valuation
Founded Year
Headquarters
Neuspera Medical develops implantable neuromodulation devices designed to treat urinary urge incontinence through advanced wireless charging technology. Based in San Jose, the company addresses a significant medical need affecting millions of patients worldwide who suffer from overactive bladder conditions. Neuspera's innovative approach combines targeted neural stimulation with convenient wireless power delivery, potentially offering patients a more user-friendly alternative to existing treatment options. The company's technology represents a notable advancement in the urological device market, where traditional solutions often require invasive battery replacement procedures. Neuspera continues to focus on advancing its neuromodulation platform for broader therapeutic applications.
Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.
Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.
